Day 3 Highlights from ASH 2024: Lymphoma Breakthroughs and Myeloma Insights

Day 3 of ASH 2024 revealed groundbreaking findings: a 97% complete response rate for zilovertamab vedotin in diffuse large B-cell lymphoma, new insights into zanubrutinib’s efficacy in chronic lymphocytic leukemia, and promising survival data for belantamab mafodotin in multiple myeloma. Like what you hear? Download Curie from the App Store for more personalized healthcare content.